A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
A Phase 1, Randomized, Double-blind, Placebo-controlled, Integrated Single Ascending Dose, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Amgen Call Center
- Phone Number: 866-572-6436
- Email: medinfo@amgen.com
Study Locations
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Clinical Medical and Analytical eXellence CMAX
-
-
-
-
-
Mechelen, Belgium, 2800
- Algemeen Ziekenhuis Sint Maarten-Emmaus vzw
-
-
-
-
Ontario
-
Winchester, Ontario, Canada, K0C 2K0
- Winchester District Memorial Hospital
-
-
-
-
-
Cambridge, United Kingdom, CB2 0AY
- VPD Heart and Lung Research Institute
-
London, United Kingdom, SW10 9NH
- Chelsea and Westminster Hospital
-
Manchester, United Kingdom, M23 9QZ
- The Medicines Evaluation Unit
-
-
-
-
California
-
Lake Forest, California, United States, 92630
- Orange County Research Center
-
-
Florida
-
Aventura, Florida, United States, 33180
- Translational Clinical Research LLC
-
Palmetto Bay, Florida, United States, 33157
- Destiny Research Center
-
-
Georgia
-
Columbus, Georgia, United States, 31904
- ClinCept, LLC
-
-
Maryland
-
White Marsh, Maryland, United States, 21162
- Chesapeake Clinical Research Inc
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham and Womens Hospital
-
South Dartmouth, Massachusetts, United States, 02747
- Mayflower Clinical
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
Saint Paul, Minnesota, United States, 55114
- Prism Research LLC dba Nucleus Network
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina Clinical and Translational Research Center
-
Monroe, North Carolina, United States, 28112
- Monroe Biomedical Research
-
Raleigh, North Carolina, United States, 27607
- North Carolina Clinical Research
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73120
- Allergy Asthma and Clinical Research Center
-
-
South Carolina
-
North Charleston, South Carolina, United States, 29406
- Monroe Biomedical Research
-
-
Texas
-
San Antonio, Texas, United States, 78240
- Endeavor Clinical Trials
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Part A and B
- Participants must be capable of giving informed consent and have provided informed consent.
- Participants must be 18 to 65, inclusive at time of signing of informed consent.
- Participants must have a Body Mass Index between 18.0 to 30 kg/m^2 and total body weight ≥ 40 kg at screening.
- Participants must be overtly healthy as determined by the investigator based on medical evaluation and study screening procedures.
- Female participants must be of non-childbearing potential.
Inclusion Part C
- Participants must be capable of giving informed consent and have provided informed consent.
- Participants must be 18 to 70, inclusive at time of signing of informed consent.
- Body mass index between 18.0 to 35 kg/m^2 and total body weight ≥ 40 kg at screening.
- Participants must have documentation of physician diagnosed asthma for ≥ 12 months prior to screening.
- Participants must have documented bronchodilator responsiveness of forced expiratory volume in 1 second (FEV1) ≥ 10% in the 10 years before screening or at the screening visit.
- Participants must have a pre-bronchodilator percent predicted FEV1 ≥ 50% at screening visit and Day -1. For participants on high-dose ICS, participants must have a percent-predicted FEV1 ≥ 70% at screening visit and on day -1.
- Participants must have peripheral blood eosinophils ≥ 200 cells/μl at screening visit and Day -1.
- Participants must have a fractional exhaled nitric oxide (FeNO) ≥ 25 ppb at screening visit and Day -1.
- Participant must not use inhaled corticosteroids (ICS) or must be treated with low-dose, medium-dose, or high-dose ICS and on a stable dose for a minimum of 12 weeks prior to screening.
Exclusion (applicable to all study parts)
- History of malignancy (except for in situ cervical cancer or surgically excised non-melanoma skin cancer occurring more than 5 years prior to randomization).
- History of anaphylaxis or hypersensitivity to biologic therapy or sensitivity to mammalian derived products.
- History of immunodeficiency or history of severe infection within the last 3 years requiring IV antibiotics.
- History of tuberculosis (TB), TB symptoms, or positive interferon gamma release assay.
- History of untreated or unresolved helminthic infection within 24 weeks of day 1.
- Positive human immunodeficiency virus (HIV) antibodies, hepatitis B core antigen, hepatitis B core antibody, or hepatitis C virus (HCV) ribonucleic acid (RNA).
- Male participants unwilling to follow contraceptive requirements.
Additional Exclusion for Part C only
- Female of childbearing potential not willing to use 2 methods of contraception with one being a highly effective method of contraception.
- History of pulmonary disease that may interfere with interpretation of study results.
- History of upper respiratory infection within 6 weeks of screening.
- Asthma Control Questionnaire (ACQ-6) > 3.
- Asthma symptoms or exacerbations requiring 2 or more systemic corticosteroid bursts (≥10 mg/day prednisone or equivalent for ≥ 3 days each) in the previous 12 months.
- More than one hospitalization or emergency department visit in the last year.
- History of life-threatening asthma exacerbation after the 12 years age requiring admission to intensive care unit.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Part A: Single Ascending Dose (SAD)
Healthy participants will be randomized in a 3:1 ratio to receive either AMG 691 or placebo.
|
SC injection
Subcutaneous (SC) injection
|
|
Experimental: Part B: Multiple Ascending Dose (MAD)
Healthy participants will be randomized in a 3:1 ratio to receive either AMG 691 or placebo.
|
SC injection
Subcutaneous (SC) injection
|
|
Experimental: Part C: Multiple Dose
Participants with mild-to-moderate asthma will be randomized in a 2:1 ratio to receive either AMG 691 or placebo.
|
SC injection
Subcutaneous (SC) injection
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
Time Frame: Up to approximately 11 months
|
An adverse event (AE) is any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with the study treatment.
TEAEs are any event that occurred after the participant received study treatment.
Serious AEs (SAEs) are defined as any untoward medical occurrence that, meet at least 1 of the following serious criteria: Immediately life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect.
Includes AEs of interest (AEOI), and AEs leading to discontinuation.
|
Up to approximately 11 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Maximum Concentration (Cmax) of AMG 691
Time Frame: Up to approximately 11 months
|
Up to approximately 11 months
|
|
Area Under the Curve (AUC) of AMG 691
Time Frame: Up to approximately 11 months
|
Up to approximately 11 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: MD, Amgen
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 20230151
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.